Screener
Xeris Biopharma Holdings, Inc. XERS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|
| Amortization of intangible assets | 5,421 | 5,421 |
| Amortization of debt discount and debt issuance costs | 1,796 | 1,664 |
| Amortization of operating right-of-use assets | 339 | 246 |
| Stock-based compensation | 15,206 | 9,451 |
| Loss on extinguishment of debt | 30,782 | — |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | (7,055) | (12,633) |
| Prepaid expenses and other current assets | (4,344) | 1,803 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s stock-based comp?
- Xeris Biopharma Holdings, Inc. (XERS) reported stock-based comp of $11.07M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s stock-based comp changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s stock-based comp increased by 121.0% year-over-year, from $5.01M to $11.07M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s stock-based comp has grown at a 18.4% compound annual growth rate (CAGR), from $11.38M to $22.37M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Xeris Biopharma Holdings, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude